Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Oxford | OTHER |
Not provided
Not provided
Not provided
Not provided
On discharge from intensive care (ICU) patients are often severely anaemic (have a low level of haemoglobin (Hb) in their red blood cells (RBC)). Anaemia can persist for many months making patients feel tired and fatigued. Regaining pre-illness health and energy levels can take a long time.
The ABC Post Intensive Care Trial will be the first trial to investigate if an anaemic ICU patient's health can be improved by treating with RBC transfusions following ICU discharge. We will compare the current approach as per national guidelines (restrictive transfusion), with a more active transfusion regime to correct anaemia from ICU discharge to hospital discharge.
The trial will take place in acute hospitals throughout the UK where patients are discharged after a period of time in ICU.
Patients discharged, or ready for discharge from ICU will be approached to consider participation in the trial. Once Hb level drops below 94g/L they would become eligible for inclusion (subject to meeting inclusion/exclusion criteria). The main indication for being excluded from participating in the trial is that transfusions are contraindicated (not appropriate for the patient) or they have an objection to blood transfusions.
Group allocation will be randomly assigned at ICU discharge. We will explore which patients benefit most from transfusions and those who gain no benefit.
Patients will have their Hb level checked at least weekly whilst in hospital and based on the result will have RBC transfusions as required according to the treatment regime they were randomised to.
Part of the research is based on self-reported quality of life so participants will be asked to complete a number of questionnaires at set time-points from randomisation to 6 months post randomisation.
Each participant will be actively on trial for approximately 6 months. The five-year follow will be done using routinely collected data from national databases.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention Group | Other | All patients will receive a single unit red blood cell (RBC) transfusion post randomisation. Single RBC transfusions will subsequently be administered to achieve and maintain haemoglobin (Hb) concentration of 100-120g/L unitl hospital discharge. Hb measured at least weekly in hospital. |
|
| Usual care group | Active Comparator | Current usual care transfusion practice, namely single RBC transfusions when Hb 70g/L or less (or modified according to clinician decision) to achieve target Hb 70-90g/L. HB measured at least weekly in hospital |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Red Blood Cells (Transfusion) | Biological | Participants will receive RBC transfusions in accordance with trial protocol (intervention group) or usual care, which is in accordance with the NICE guidelines |
| Measure | Description | Time Frame |
|---|---|---|
| Physical component score (PCS) of the SF-36 Health Related Quality of Life (HRQoL) questionnaire at 3 months post randomisation | 3 months post randomisation |
| Measure | Description | Time Frame |
|---|---|---|
| PCS of the SF-36 HRQoL questionnaire (and its four sub-domains) at 1 and 6 months post randomisation. | 6 months post randomisation | |
| Patient Fatigue (Fatigue Severity Scale (FSS)) at 1, 3 and 6 months post randomisation | 6 months post randomisation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NHS Lothian | Edinburgh | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41244217 | Derived | Walsh TS, Emerson L, Singleton J, Locherty R, Hope D, Cholbi S, Giddings A, Macdonald A, Lone N, Docherty AB, Mead G, Stanworth SJ, Drakesmith A, Roy NBA, Hall P, Neilson AR, Pollock R, Rodriguez A, Norrie J, Weir CJ, Shah A, Griffith D. Anaemia management with red blood cell transfusion to improve post-intensive care disability: Protocol for the ABC post-ICU randomised controlled trial. J Intensive Care Soc. 2025 Nov 12;27(1):98-106. doi: 10.1177/17511437251374884. eCollection 2026 Feb. | |
| 38780066 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005221 | Fatigue |
| ID | Term |
|---|---|
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004906 | Erythrocyte Count |
| D001803 | Blood Transfusion |
| ID | Term |
|---|---|
| D001772 | Blood Cell Count |
| D002452 | Cell Count |
| D003584 | Cytological Techniques |
| D019411 | Clinical Laboratory Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Mental Component Score of SF-36 (and its four sub-domains) at 1, 3 and 6 months post randomisation | 6 months post randomisation |
| Activities of Daily Living (ADLs) (from WHODAS questionnaire) at 3 months post randomisation | 3 months post randomisation |
| Patients alive at 1, 3, and 6 months post-randomisation | 6 months post randomisation |
| Patients alive at 5 years post-randomisation derived from data linkage | 5 years post randomisation |
| Haemoglobin concentration at 1 month post-randomisation | 1 month post randomisation |
| Post-ICU length of hospital stay | Variable according to patient's length of hospital stay |
| Care costs during 6 months post-randomisation | 6 months post randomisation |
| Incremental cost per QALY at 6 months | 6 months post randomisation |
| Care costs derived from data linkage during 5 years post-randomisation | 5 years post randomisation |
| Protocol compliance (during intervention index hospital stay) | Proportion of participants compliant with the study intervention as per protocol (%). | Throughout the study, for an average of 1 month |
| Hb concentration (during index hospital stay) | Throughout the study, for an average of 1 month |
| RBC use (during 3 months follow up) | 3 months post randomisation |
| New Infections (during 3 months follow-up) | 3 months post randomisation |
| Transfusion-related adverse events (during 3 months follow-up) | 3 months post randomisation |
| Major adverse cardiovascular events (MACE; during 3 months follow-up) | 3 months post randomisation |
| Derived |
| Radford M, Estcourt LJ, Sirotich E, Pitre T, Britto J, Watson M, Brunskill SJ, Fergusson DA, Doree C, Arnold DM. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. Cochrane Database Syst Rev. 2024 May 23;5(5):CD011305. doi: 10.1002/14651858.CD011305.pub3. |
| D019937 |
| Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D006403 | Hematologic Tests |
| D008919 | Investigative Techniques |
| D002468 | Cell Physiological Phenomena |
| D001790 | Blood Physiological Phenomena |
| D002943 | Circulatory and Respiratory Physiological Phenomena |
| D001691 | Biological Therapy |
| D013812 | Therapeutics |